About Rinske Wijtmans

This author has not yet filled in any details.
So far Rinske Wijtmans has created 7 blog entries.

OpEd: Mark Trusheim & Peter B. Bach on How the US Can Beat Hepatitis C

How the US Can Beat Hepatitis C: Don’t buy the pills, buy the company
Pharma veteran and physician advance provocative solution to overcome treatment costs

CAMBRIDGE, MASSACHUSETTS—In an article published today in Forbes, Visiting Scientist at the MIT Sloan School of Management Mark Trusheim and co-author Peter B. Bach, a physician at Memorial Sloan Kettering Cancer […]

Gerald J. Dal Pan: “Assessing the Impact of Postmarketing Regulatory Programs and Actions”

November 28, 2016
Massachusetts Institute of Technology
By invitation only

The FDA’s Director of the Office of Surveillance and Epidemiology in FDA’s Center for Drug Evaluation and Research will deliver the address, “Assessing the Impact of Postmarketing Regulatory Programs and Actions.”

Gerald J. Dal Pan, MD, MHS currently serves as the Director of the Office of Surveillance and Epidemiology […]

Special Issue of Clinical Pharmacology & Therapeutics spotlights Adaptive Biomedical Innovation

Expert views on strategies for getting new science to patients faster, safely, and affordably

CAMBRIDGE, Mass., Nov. 9, 2016—Clinical Pharmacology & Therapeutics (CPT), a cross-disciplinary journal in experimental and clinical medicine, in collaboration with the MIT Center for Biomedical Innovation (CBI) and its New Drug Development Paradigms (NEWDIGS) initiative, published a special issue today focusing on […]

NEWDIGS convenes healthcare leaders to pioneer new pharmaceutical financing strategies

CAMBRIDGE, Mass., Oct. 27, 2016 — Patient advocates, healthcare payers, industry, and academic stakeholders gathered today at the Massachusetts Institute of Technology (MIT) to map out a new strategy for designing and piloting innovative financing and reimbursement models for promising, and possibly curative, new medicines. The project is called Financing and Reimbursement of Cures in […]

European Rare Diseases advocate EURORDIS joins as NEWDIGS member

International collaboration aims to improve healthcare for people living with a rare disease

BOSTON, PARIS, 1 JULY 2016—MIT’s NEW Drug Development ParadIGmS (NEWDIGS) program announced today that EURORDIS-Rare Diseases Europe, the European Organisation for Rare Diseases, has joined its international effort to accelerate delivery of new, better, affordable therapeutics to patients faster. NEWDIGS brings together pharmaceutical and biotech companies, regulators, insurers, patient advocacy groups, and other healthcare stakeholders to design modern systems that connect scientific discovery to patient care. […]

Gigi Hirsch with Alberto Grignolo on DIA Global Forum Podcast: “An Urgent Imperative Now to Learn Quickly”

Listen to a conversation between Dr. Alberto Grignolo, Deputy Editor of DIA Global Forum, and NEWDIGS Executive Director and DIA 2016 Conference Co-Chair Dr. Gigi Hirsch discuss the challenges of healthcare system redesign in an era of groundbreaking science and new medical therapies.

Dr Hirsch is also participating in the DIA 2016 panel discussion “Europe and […]

Mark Trusheim featured in Nature News Article: Financing Cures

Mark Trusheim, Director of NEWDIGS Strategic Initiatives, is quoted in the Nature News article “Promising gene therapies pose million-dollar conundrum“. He spoke at BIO on June 8th presenting on “Curative Therapies: Aligning Policy with Science to Ensure Patient Access.”

NEWDIGS will soon be launching a project on financing and reimbursement of cures in the US […]